title: [Olanzapine versus haloperidol: effectiveness in functionality and health state in a sample of Venezuelan patients with schizophrenia].
abstract: OBJECTIVE
  To compare olanzapine versus haloperidol effectiveness, in terms of relapse rates in Venezuelan patients with schizophrenia.
  
  
  METHODS
  A randomized, open label, follow-up study of 9-months after clinical stabilization or hospital discharged was conducted. The Medical Outcomes Study Form Health Survey (SF-36) and the Quality of Life Index from Mezzic & Cohen were used to evaluate the health state and quality of life. Safety parameters were collected.
  
  
  RESULTS
  Thirty-one patients in olanzapine and 40 in haloperidol were enrolled and discontinuation rates were 65% and 68% respectively. Only one patient in haloperidol relapsed. Health status improved more with olanzapine showing statistically significant improvement in five of the eight items of the SF-36. Olanzapine was slightly superior improving quality of life. More adverse events were registered with haloperidol (p = 0.036). More extrapyramidal symptoms, akathisia and insomnia were reported with haloperidol and more weight gain with olanzapine but the differences were not significant.
  
  
  CONCLUSIONS
  Both medications were similar preventing relapses. Health status and functionality improved more with olanzapine versus haloperidol. Safety results are consistent with the known profile of the drug. Study limitations on design and conduction of this study restrict its generalization.
authors.affiliation: Gerente Médico de Investigación Clínica en Neurociencias, Eli Lilly & Co. Afiliada LACMASS, Lima, Perú. Adrianzen_Cecilia@Lilly.com
authors.forename: Cecilia
authors.initials: C
authors.lastname: Adrianzén
authors.forename: Miriam
authors.initials: M
authors.lastname: Sánchez
authors.forename: Jesús
authors.initials: J
authors.lastname: Córdova
authors.forename: Ingrid
authors.initials: I
authors.lastname: Castillo
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D016009:Chi-Square Distribution; D003627:Data Interpretation, Statistical; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D000077152:Olanzapine; D011788:Quality of Life; D012008:Recurrence; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014687:Venezuela
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine